Clinical Trials

Melanoma

NCT06646016 2025-12-26

EPIC

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT06626256 2025-12-24

STIL101 for Injection for the Treatment of Locally Advanced, Metastatic or Unresectable Pancreatic Cancer, Colorectal Cancer, Renal Cell Cancer, Cervical Cancer and Melanoma

DermatologicGastrointestinalGenitourinaryGynecologic

Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Melanoma, Neoplasm Metastasis, Pancreatic Neoplasms, Colorectal Neoplasms

NCT01861938 2025-10-02

Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients

Phase 2/3 Withdrawn

Melanoma, Neoplasm Metastasis

NCT05717140 2025-08-07

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Melanoma

NCT06508827 2025-07-09

Intravenous Iron in Combination With Standard of Care Immunotherapy in Melanoma

Classical hematologyDermatologic

Anemia, Melanoma, Anemia, Iron-Deficiency

NCT06190249 2025-06-05

Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

Melanoma

NCT00535314 2025-05-31

Study of Two Dose Levels of RTA 402 in Patients With Advanced Malignant Melanoma

Melanoma

NCT02145910 2025-05-02

Vemurafenib Combined With Whole Brain Radiation Therapy or Radiosurgery in Patients With BRAF Mutation-Positive Melanoma and Brain Metastases

CNSDermatologic

Brain Neoplasms, Melanoma

NCT03167177 2025-02-21

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Melanoma

NCT03448666 2024-09-23

ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases

Melanoma

NCT02535078 2024-07-24

Phase 1b/2 Study of the Combination of IMCgp100 With Durvalumab and/or Tremelimumab in Advanced Cutaneous Melanoma

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma

NCT04242329 2024-01-26

SUMMIST

Melanoma

NCT05482074 2024-01-19

Olaparib in Unresectable/Metastatic Melanoma With BRCA1/2

Uveal Melanoma, Melanoma

NCT00979693 2023-12-26

Psilocybin-Assisted Psychotherapy for Anxiety in People With Stage IV Melanoma

Anxiety Disorders, Depression, Melanoma, Pain

NCT02143050 2023-11-18

Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients

Melanoma

NCT06090318 2023-10-19

Milademetan in Combination With Atezolizumab in Patients With Advanced Solid Tumors With CDKN2A Loss

DermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Renal Cell, Melanoma, Mesothelioma, Stomach Neoplasms

NCT05299580 2023-09-14

"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"

Melanoma

NCT05561491 2023-06-22

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients

Melanoma, Neoplasm Metastasis

NCT04987996 2023-06-06

GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Melanoma

NCT04703426 2023-05-22

Sargramostim (GM-CSF) + PD-1

Melanoma

NCT05496192 2023-04-14

A Study of Nivolumab Intravenous (IV) to Subcutaneous (SC) Switch in Adjuvant Melanoma and Bladder Cancer

DermatologicGenitourinary

Carcinoma, Transitional Cell, Melanoma

NCT04759846 2023-02-21

Hepatic Impairment Study of Encorafenib in Combination With Binimetinib in BRAF Melanoma

BreastDermatologicHead & NeckThoracic

Melanoma

NCT04941365 2022-12-22

SERPENTINE

Phase NA Withdrawn

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT05572463 2022-11-18

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Melanoma, Neoplasms

NCT03754140 2022-07-14

INTRANS

Phase EARLY_PHASE1 Withdrawn

Melanoma

NCT04891718 2022-07-08

CIVO Intratumoural Microdosing of Anti-Cancer Therapies in Australia

DermatologicHead & NeckLymphoidSarcoma

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms, Lymphoma, Melanoma, Sarcoma

NCT04648826 2021-12-17

Aerosolized Azacytidine as Epigenetic Priming for Bintrafusp Alfa-Mediated Immune Checkpoint Blockade in Patients With Unresectable Pulmonary Metastases From Sarcomas, Germ Cell Tumors, or Epithelial Malignancies

DermatologicGenitourinarySarcoma

Carcinoma, Renal Cell, Melanoma, Neoplasms, Germ Cell and Embryonal, Sarcoma

NCT04223648 2021-11-22

Programmed Cell Death 1 + Selected Cell Therapy With Durvalumab (MEDI4736) and Tremelimumab in Metastatic Melanoma

Phase EARLY_PHASE1 Withdrawn

Melanoma

NCT04995094 2021-11-05

Study of Neoadjuvant Imprime PGG and Pembrolizumab for Stage III, Resectable Melanoma

Melanoma

NCT04955262 2021-07-08

A CD8 Positron Emission Tomography With Computed Tomography (PET/CT) Study Using ⁸⁹Zr Df-IAB22M2C in Patients With Metastatic Melanoma Receiving Bempegaldesleukin (NKTR-214) and Nivolumab

Melanoma

NCT04060407 2021-06-01

CINDI

Melanoma

NCT04042506 2021-04-12

SBRT as a Vaccination for Metastatic Melanoma

Melanoma

NCT03773744 2021-04-06

Pelican

Melanoma

NCT04495010 2021-03-19

CheckMate 7UA

Melanoma

NCT03758729 2021-02-16

Phase II Study of Nivolumab in Combination With Radiation Therapy as Definitive Treatment for Patients With Locally Advanced, Unresectable Head and Neck Mucosal Melanoma.

Melanoma

NCT03972046 2020-10-19

Neoadjuvant Use of Talimogene Laherparepvec and BRAF/MEK Inhibitor for Advanced Nodal BRAF Mutant Melanoma

Melanoma, Skin Neoplasms

NCT03126461 2020-08-20

SAbR Plus Ipilimumab Plus Nivolumab in Metastatic Melanoma Patients

Melanoma

NCT01826864 2020-07-27

Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Phase 3 Withdrawn

Melanoma

NCT02263898 2020-07-27

Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase EARLY_PHASE1 Withdrawn

Melanoma

NCT04285749 2020-07-27

Prevention of Recurrence and Metastasis in Genetically High-Risk Melanomas

Melanoma

NCT01355562 2020-04-30

Trial of Outpatient Intravenous Interleukin-2 in Malignant Melanoma and Metastatic Kidney Cancer

DermatologicGenitourinary

Kidney Neoplasms, Melanoma

NCT04125719 2020-02-11

PPD1

Melanoma

NCT04007588 2020-02-05

A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma

Melanoma

NCT03982134 2019-10-04

PDR001 + Panobinostat for Melanoma and NSCLC

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT03111901 2019-07-12

UVA-AM-002

DermatologicGenitourinary

Carcinoma, Renal Cell, Melanoma

NCT02300935 2019-05-30

Study of Trametinib and Nab-paclitaxel in Patients With Melanoma

Melanoma, Neoplasm Metastasis

NCT03518229 2019-04-17

Pilot Study of Intervention to Reduce Sunburns in Melanoma Survivors

Phase NA Withdrawn

Melanoma, Sunburn

NCT02068079 2019-01-30

A Pilot Study of Trientine With Vemurafenib for the Treatment BRAF Mutated Metastatic Melanoma